COPD Connect
  • Saved
Small Airways: The "Silent Zone" of 2021 GINA Report?

Small Airways: The "Silent Zone" of 2021 GINA Report?

Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.884679/full

Asthma is a chronic disease, affecting approximately 350 million people worldwide. Inflammation and remodeling in asthma involve the large airways, and it is now widely accepted that the small airways...


Conclusion/Relevance: SAD appears to possess the characteristics of a treatable pulmonary trait, making it certainly appealing for asthma control optimization and exacerbation rate reduction. In this mini-review article, we address the most recent evidence on the role of SAD on asthma control and critically review the possible inclusion of SAD...

  • Saved
Tiotropium and treatable traits in ACO | JAA

Tiotropium and treatable traits in ACO | JAA

Source : https://www.dovepress.com/tiotropium-add-on-and-treatable-traits-in-asthma-copd-overlap-a-real-w-peer-reviewed-fulltext-article-JAA

Asthma is a common disorder with variable severity characterized by reversible airway obstruction, airway hyperresponsiveness (AHR), and chronic airway inflammation. According to worldwide surveys, approximately 350 million individuals currently suffer...


Conclusion: TIO add-on therapy to FP/FM in patients with ACO, considered difficult to treat because of the presence of both asthma and COPD, resulted in improvements in lung function parameters in this real-world pilot study, indicating the potential value of TIO add-on therapy as a “treatable traits” option for standard treatment for ACO.

  • Saved
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial

Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial

Source : https://www.atsjournals.org/doi/10.1164/rccm.202201-0206OC

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more.



Conclusions: Losartan did not prevent emphysema progression in people with COPD with mild-moderate emphysema.

  • Saved
Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Source : https://www.hindawi.com/journals/cin/2022/5740181/

Objective . The main objective is to investigate the effect of Yifei-Huoxue decoction combined with tiotropium on the inflammatory cytokine levels, pulmonary function, and quality of life in patients with...


Relevance:
The main objective is to investigate the effect of Yifei-Huoxue decoction combined with tiotropium on the inflammatory cytokine levels, pulmonary function, and quality of life in patients with chronic obstructive pulmonary disease (COPD).


  • Saved

Effectiveness of COPD treatment with the combination of tiotropium/olodaterol in Polish standard clinical practice as measured by the improvement of CCQ: an observational study

Source : https://www.mp.pl/paim/issue/article/16268/

Introduction: COPD health-related quality of life (HRQoL) can be measured by the Clinical COPD Questionnaire (CCQ). In this study the CCQ was used to assess the therapeutic success of fixed-dose...


Conclusions:
Tiotropium/olodaterol treatment improved clinical control in Polish COPD patients. The therapeutic success was the most pronounced in patients with more severe COPD and in the treatment-naive but occurred also in those with moderate disease and in previously treated subjects.